Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16038707rdf:typepubmed:Citationlld:pubmed
pubmed-article:16038707lifeskim:mentionsumls-concept:C0225828lld:lifeskim
pubmed-article:16038707lifeskim:mentionsumls-concept:C0007587lld:lifeskim
pubmed-article:16038707lifeskim:mentionsumls-concept:C0022116lld:lifeskim
pubmed-article:16038707lifeskim:mentionsumls-concept:C0040018lld:lifeskim
pubmed-article:16038707lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:16038707lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:16038707lifeskim:mentionsumls-concept:C0035124lld:lifeskim
pubmed-article:16038707pubmed:issue2lld:pubmed
pubmed-article:16038707pubmed:dateCreated2005-7-25lld:pubmed
pubmed-article:16038707pubmed:abstractTextThrombin exerts multiple actions on cardiomyocytes leading to increased intracellular Na+ and Ca2+ concentrations, and to activation of a Ca2+-independent PLA2, and has been proposed to favor the genesis of arrhythmias and ischemic injury in acute coronary syndromes. However, the influence of thrombin on cardiomyocyte cell death during ischemia-reperfusion has not been studied. A beneficial influence of low thrombin concentrations has been described in other cell types. HL-1 cardiomyocytes were subjected to simulated ischemia (SI) and reperfusion (SR) and cell death was assessed by means of LDH release to the incubation media. Thrombin dose-dependently increased cell death in normoxic cells, in cells subjected to SI, and in cells subjected to SR (by 20+/-8%, 95+/-32% and 35+/-9%, respectively, at 100 U/ml). The effects of thrombin were associated to increased cytosolic Ca2+ overload, mimicked by 100 microM PAR-1 agonist peptide SFLLRNPNDKYEPF, and reversed by the direct thrombin inhibitor lepirudin (IC50=1.3+/-0.2 microg/ml). The presence of thrombin during simulated ischemia-reperfusion increases cardiomyocyte cell death by a mechanism that involves activation of PAR-1 receptors and can be prevented by the direct thrombin inhibitor lepirudin.lld:pubmed
pubmed-article:16038707pubmed:languageenglld:pubmed
pubmed-article:16038707pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:citationSubsetIMlld:pubmed
pubmed-article:16038707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16038707pubmed:statusMEDLINElld:pubmed
pubmed-article:16038707pubmed:monthAuglld:pubmed
pubmed-article:16038707pubmed:issn0022-2828lld:pubmed
pubmed-article:16038707pubmed:authorpubmed-author:BarrabésJosé...lld:pubmed
pubmed-article:16038707pubmed:authorpubmed-author:Garcia-Dorado...lld:pubmed
pubmed-article:16038707pubmed:authorpubmed-author:MirabetMaribe...lld:pubmed
pubmed-article:16038707pubmed:authorpubmed-author:Ruiz-MeanaMar...lld:pubmed
pubmed-article:16038707pubmed:authorpubmed-author:Soler-SolerJo...lld:pubmed
pubmed-article:16038707pubmed:issnTypePrintlld:pubmed
pubmed-article:16038707pubmed:volume39lld:pubmed
pubmed-article:16038707pubmed:ownerNLMlld:pubmed
pubmed-article:16038707pubmed:authorsCompleteYlld:pubmed
pubmed-article:16038707pubmed:pagination277-83lld:pubmed
pubmed-article:16038707pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:meshHeadingpubmed-meshheading:16038707...lld:pubmed
pubmed-article:16038707pubmed:year2005lld:pubmed
pubmed-article:16038707pubmed:articleTitleThrombin increases cardiomyocyte acute cell death after ischemia and reperfusion.lld:pubmed
pubmed-article:16038707pubmed:affiliationServicio de Cardiología, Hospital Universitari Vall d'Hebron, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain.lld:pubmed
pubmed-article:16038707pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16038707pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16038707lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16038707lld:pubmed